Celgene

Cyteir Therapeutics, Inc. focuses on developing innovative therapeutics that harness the biology of DNA repair to treat cancer and address autoimmune diseases through synthetic lethality. The company manufactures targeted therapeutics designed to induce the self-destruction of diseased cells by overwhelming them with DNA damage. Utilizing an integrated drug development platform, Cyteir aims to balance DNA damage and repair mechanisms to achieve therapeutic effects. Its diverse pipeline includes small molecule therapeutics intended for various applications, particularly in hematological malignancies, solid tumors, and chronic autoimmune disorders. Founded in 2012 and headquartered in Lexington, Massachusetts, Cyteir Therapeutics is committed to overcoming significant challenges in oncology, such as minimizing side effects, reducing therapy resistance, and promoting the self-destruction of cancerous cells.

Anokion SA is a biotechnology company based in Ecublens, Switzerland, specializing in antigen-specific immune tolerance solutions. As a spin-off from the Ecole Polytechnique Fédérale de Lausanne, Anokion develops innovative therapies aimed at reducing the immunogenicity of therapeutic proteins. The company's platform technology is designed to address a range of autoimmune and allergic diseases, including prevalent conditions such as celiac disease, multiple sclerosis, and type 1 diabetes. By engineering proteins or antigens, Anokion’s approach provides precise therapies that minimize side effects and enhance patient outcomes in the treatment of autoimmune disorders.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.

Aitia is a big data analytics company that specializes in providing solutions for the healthcare industry. The firm utilizes advanced analytics to uncover effective treatments and identify the right patient populations. Aitia's Reverse Engineering and Forward Simulation Technology enables the automated extraction of causal network models from observational data, facilitating high-throughput simulations to generate new insights. The company offers real-world outcomes solutions derived from various data sources, including electronic health records and claims data, and supports product development for biopharmaceutical firms, diagnostic companies, and medical device manufacturers. Aitia serves a diverse clientele, including pharmaceutical and biotechnology companies, health plans, hospitals, and accountable care organizations. Founded in 2000 and based in Cambridge, Massachusetts, Aitia operates as a subsidiary of Via Science, Inc.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.

Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York, New York. It is focused on developing innovative therapeutics aimed at preventing cancer relapse and metastasis. The company's pipeline targets adaptive stress pathways and immune modulation to address treatment resistance, which is a significant factor in cancer-related deaths. HiberCell employs advanced artificial intelligence and machine learning techniques to analyze multi-omic and phenotypic profiles of tumors, generating insights that link this data to clinical outcomes. By doing so, HiberCell aims to enhance treatment strategies and ultimately help patients achieve longer, cancer-free lives. The company is supported by prominent investors in the biotechnology sector who share its vision of transforming the approach to metastatic cancer treatment.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York, New York. It is focused on developing innovative therapeutics aimed at preventing cancer relapse and metastasis. The company's pipeline targets adaptive stress pathways and immune modulation to address treatment resistance, which is a significant factor in cancer-related deaths. HiberCell employs advanced artificial intelligence and machine learning techniques to analyze multi-omic and phenotypic profiles of tumors, generating insights that link this data to clinical outcomes. By doing so, HiberCell aims to enhance treatment strategies and ultimately help patients achieve longer, cancer-free lives. The company is supported by prominent investors in the biotechnology sector who share its vision of transforming the approach to metastatic cancer treatment.

Biond Biologics Ltd is a drug discovery and development company based in Misgav, Israel, established in 2016. The company specializes in creating immuno-oncology drugs for cancer treatment and therapies for autoimmune diseases. Biond Biologics is focused on translating high-quality scientific research into innovative therapies that address unmet medical needs. Its novel platform also allows for antibody-targeting of intracellular immune factors, positioning the company within the evolving fields of cancer immunotherapy and autoimmune disorder treatments. By combining advanced scientific expertise with innovative approaches, Biond Biologics aims to contribute significantly to the development of breakthrough therapies in these critical areas.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.

Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in developing innovative oncology therapies aimed at treating various types of cancer. Its product pipeline includes ATG-008, an orally available mTOR kinase inhibitor for advanced solid tumors and hematological malignancies, and ATG-010, a compound targeting the XPO1 protein for hematologic cancers like multiple myeloma. Additionally, Antengene is advancing several other candidates in different stages of development, including ATG-016, ATG-527, and ATG-019, which target various oncological conditions. The company is committed to addressing unmet medical needs in Asia through its research and development efforts focused on anti-tumor and anti-cancer therapies.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, founded in 2008. The company has developed an innovative platform known as the CIVO arrayed microinjection system, which allows for the simultaneous evaluation of multiple drugs or drug combinations directly within a patient's tumor. This technology assesses efficacy, resistance, and drug synergies in the tumor's native microenvironment, overcoming the limitations of traditional systemic drug administration. By employing its clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, thereby streamlining drug development. Additionally, the technology facilitates the identification of effective drug combinations and targets using RNA interference, providing a more accurate measurement of treatment efficacy tailored to individual patient responses.

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

Skyhawk Therapeutics is focused on the discovery and development of small molecule therapeutics aimed at correcting RNA expression. The company utilizes proprietary technology to design small molecules that specifically target binding pocket regions on RNA, ensuring both sequence and structural specificity during critical phases of RNA splicing. This innovative approach enables the development of therapies for various conditions, including cancer, neurological disorders, and rare diseases, particularly those associated with RNA mis-splicing known as exon skipping. Founded in 2015 and headquartered in Waltham, Massachusetts, Skyhawk Therapeutics was previously known as Rare Genetix before rebranding in 2018.

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

Cyteir Therapeutics, Inc. focuses on developing innovative therapeutics that harness the biology of DNA repair to treat cancer and address autoimmune diseases through synthetic lethality. The company manufactures targeted therapeutics designed to induce the self-destruction of diseased cells by overwhelming them with DNA damage. Utilizing an integrated drug development platform, Cyteir aims to balance DNA damage and repair mechanisms to achieve therapeutic effects. Its diverse pipeline includes small molecule therapeutics intended for various applications, particularly in hematological malignancies, solid tumors, and chronic autoimmune disorders. Founded in 2012 and headquartered in Lexington, Massachusetts, Cyteir Therapeutics is committed to overcoming significant challenges in oncology, such as minimizing side effects, reducing therapy resistance, and promoting the self-destruction of cancerous cells.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.

Celularity is a clinical-stage biotechnology company focused on developing innovative therapies using allogeneic cells and tissues derived from postpartum placenta. The company specializes in off-the-shelf placental-derived cell therapies, including both genetically modified and unmodified natural killer (NK) cells, engineered T cells such as CAR-T cells, and mesenchymal-like adherent stromal cells. These therapies are designed to treat a range of conditions, including cancer, autoimmune diseases, and degenerative disorders, while also enhancing immunity and promoting healing. Celularity operates through three main business segments: Cell Therapy, Degenerative Disease, and bio-banking, with the bio-banking segment contributing the majority of its revenue. The company aims to enable patients to initiate treatment more rapidly, thereby improving medical outcomes.

Juno Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell-based cancer immunotherapies using chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically modify T cells to target and eliminate cancer cells. The company is advancing a diverse pipeline of product candidates, including JCAR017 and JCAR014 for relapsed or refractory B cell malignancies, and JCAR018 for pediatric patients with CD22-positive cancers. Additional candidates include therapies targeting neuroblastoma, lung cancer, ovarian cancers, and glioblastoma, among others. Juno Therapeutics collaborates with prominent cancer research institutions such as Fred Hutchinson Cancer Research Center and Memorial Sloan Kettering Cancer Center to enhance its research and development efforts. Founded in 2013 and headquartered in Seattle, Washington, Juno Therapeutics has established itself as a leader in immunotherapy innovation and operates as a subsidiary of Bristol-Myers Squibb Company.

Impact Biomedicines, Inc. engages in the research, development, and commercialization of treatments for patients with myeloproliferative neoplasms and other cancers. Its product under late-stage development pipeline is fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded in 2016 and is headquartered in San Diego, California. As of February 28, 2018, Impact Biomedicines, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the discovery and development of oral small molecule therapies for oncology and inflammatory diseases. The company is focused on addressing significant unmet medical needs through its proprietary discovery engine. Its lead oncology candidate, FLX475, is a C-C motif chemokine receptor 4 antagonist currently undergoing Phase 2 clinical trials, both as a monotherapy and in combination with pembrolizumab, for various tumor types. Additionally, RAPT's lead inflammation drug candidate, RPT193, aims to selectively inhibit the migration of type 2 T helper cells into allergically inflamed tissues. The company is also exploring other potential targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are in the discovery phase. Founded in 2015, RAPT Therapeutics was previously known as FLX Bio, Inc. before its name change in May 2019.

Evelo Biosciences is a biotechnology company focused on developing oral biologics, specifically monoclonal microbials, for treating a range of inflammatory diseases and cancers. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company is advancing several candidates through various stages of clinical development. EDP1815, currently in a Phase 1b clinical study, aims to treat psoriasis and atopic dermatitis, while other candidates in pre-clinical stages target conditions such as psoriatic arthritis, asthma, and neuro-inflammatory diseases. Additionally, EDP1503 is undergoing Phase 1/2 trials for colorectal cancer and other malignancies. By utilizing naturally occurring monoclonal microbials, Evelo seeks to revolutionize drug discovery and development, offering a new approach to modulating systemic immunology and biology through oral delivery. This innovative platform has the potential to enhance the efficiency and effectiveness of treatments across various health conditions.

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.

Dragonfly Therapeutics, Inc. develops drugs to stimulate immune responses against cancer using its platform TriNKET. Dragonfly Therapeutics, Inc. has strategic collaborations with Celgene Corporation and Merck. The company was founded in 2015 and is based in Waltham, Massachusetts.

Aadi Bioscience, Inc. is a clinical stage biopharmaceutical company based in Pacific Palisades, California, founded by Dr. Neil Desai in 2011. The company focuses on the development of a potentially best-in-class mTOR inhibitor, specifically ABI-009, aimed at treating patients with oncology, cardiovascular, and metabolic diseases. Aadi Bioscience is dedicated to addressing unmet medical needs through its innovative therapeutic approaches in these areas.

Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.

Delinia, Inc. is a biotechnology company based in San Francisco, California, dedicated to developing innovative therapeutics for autoimmune and inflammatory diseases. Founded in 2014, Delinia's primary focus is on a lead program that involves a molecule designed to selectively potentiate and expand regulatory T cells (Tregs), which play a vital role in maintaining self-tolerance and immune system balance. The company's scientific founders and experienced leadership team are committed to advancing its therapeutic programs toward clinical application. As of 2017, Delinia operates as a subsidiary of Celgene Corporation.

Anokion SA is a biotechnology company based in Ecublens, Switzerland, specializing in antigen-specific immune tolerance solutions. As a spin-off from the Ecole Polytechnique Fédérale de Lausanne, Anokion develops innovative therapies aimed at reducing the immunogenicity of therapeutic proteins. The company's platform technology is designed to address a range of autoimmune and allergic diseases, including prevalent conditions such as celiac disease, multiple sclerosis, and type 1 diabetes. By engineering proteins or antigens, Anokion’s approach provides precise therapies that minimize side effects and enhance patient outcomes in the treatment of autoimmune disorders.

Acetylon Pharmaceuticals, Inc. is focused on developing small molecule drugs that target epigenetic mechanisms to improve therapeutic outcomes in cancer and other serious diseases. Established in 2008 and headquartered in Boston, Massachusetts, the company has created a proprietary platform that has led to a portfolio of optimized selective compounds for oral administration, specifically targeting Class I and Class II histone deacetylases. Among its lead drug candidates are ACY-1215 and ACY-241, which are selective HDAC6 inhibitors currently undergoing Phase 2 and Phase 1b clinical trials for the treatment of multiple myeloma. Acetylon Pharmaceuticals operates as a subsidiary of Celgene Corporation, emphasizing its commitment to addressing critical unmet medical needs through innovative epigenetic therapies.

EngMab AG is a start-up biotechnology company based in Pfaffikon, Switzerland, founded in 2013. It specializes in developing engineered monoclonal antibody-based molecules aimed at enhancing immune responses against tumors. The company's key projects include T-cell bispecific antibodies designed to address significant unmet medical needs in hematological malignancies, as well as targeting tumor antigens present in both hematological and solid tumors. EngMab is funded by private Swiss investors and operates as a subsidiary of Celgene Corporation.

Arcus Biosciences is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies through insights in immunology. Founded in 2015 by experienced researchers from the biotechnology sector, the company is advancing a pipeline that includes several promising candidates. Notably, it is developing AB928, a dual A2a/A2b adenosine receptor antagonist, and Zimberelimab, an anti-PD-1 monoclonal antibody, both currently in clinical trials. Additionally, Arcus is working on AB154, an anti-TIGIT monoclonal antibody, and AB680, a small-molecule CD73 inhibitor, targeting various cancer types such as non-small cell lung cancer and pancreatic cancer. The company has established partnerships with organizations like Strata Oncology and AstraZeneca to enhance its research efforts and expand its clinical trials. By focusing on the ATP-adenosine pathway, which plays a crucial role in tumor immunosuppression, Arcus aims to create and optimize differentiated immuno-oncology therapies for patients.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.

Oncorus, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently in Phase I clinical trials aimed at treating various cancers. In addition to ONCR-177, Oncorus is advancing the ONCR-GBM program for brain cancer and exploring synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has entered a collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s immunotherapy. Founded in 2015 and headquartered in Cambridge, Massachusetts, Oncorus is committed to advancing cancer care and has pledged to support cancer research and healthcare initiatives in developing regions through corporate philanthropy.

Sapience Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of peptide-based therapeutics aimed at treating high mortality cancers. Founded in 2015 and headquartered in Harrison, New York, the company focuses on advancing innovative treatments for major unmet medical needs, particularly glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Its lead product, ST101, functions as an inhibitor of C/EBPß, a transcription factor that is often overexpressed in various cancers and plays a role in cellular differentiation, tumor survival, and proliferation. ST101 targets and reduces the expression of several genes and proteins linked to cancer cell survival and growth, inducing selective cytotoxicity across multiple tumor types, including breast cancer, melanoma, prostate cancer, GBM, lung cancer, and acute myeloid leukemia. Through its research, Sapience Therapeutics aims to translate scientific advancements into effective therapies that address oncogenic and immune dysregulation in cancer.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

Agenovir Corporation is focused on the research and development of antiviral therapeutics aimed at addressing diseases related to latent or persistent viral reservoirs. Established in 2014 and based in South San Francisco, California, the company employs innovative nucleases, including CRISPR/Cas9 technology, to target and disrupt viral DNA. This approach allows for the creation of a new class of nucleic acid-based antiviral treatments that aim to eliminate pathogenic viral genomes. Agenovir's mission is to provide effective solutions for healthcare providers treating patients suffering from severe and chronic viral infections, ultimately advancing the field of antiviral therapeutics. As of January 31, 2019, Agenovir operates as a subsidiary of Vir Biotechnology, Inc.

IDEAYA Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, dedicated to the discovery and development of targeted therapeutics for genetically defined patient populations. The company specializes in precision medicine using molecular diagnostics and synthetic lethality approaches to address cancer treatment. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently undergoing Phase 1/2 clinical trials for cancers associated with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting various mechanisms related to DNA damage and repair, such as MAT2A for tumors with MTAP deletions, Pol-theta for homologous recombination deficiency, and PARG for BRCA2 mutation context. The company collaborates with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, while also engaging in partnerships for clinical trials with Pfizer and GlaxoSmithKline. Founded in 2015, IDEAYA aims to advance innovative therapies for enhancing immunotherapy responses and improving patient outcomes in oncology.

RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the discovery and development of oral small molecule therapies for oncology and inflammatory diseases. The company is focused on addressing significant unmet medical needs through its proprietary discovery engine. Its lead oncology candidate, FLX475, is a C-C motif chemokine receptor 4 antagonist currently undergoing Phase 2 clinical trials, both as a monotherapy and in combination with pembrolizumab, for various tumor types. Additionally, RAPT's lead inflammation drug candidate, RPT193, aims to selectively inhibit the migration of type 2 T helper cells into allergically inflamed tissues. The company is also exploring other potential targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are in the discovery phase. Founded in 2015, RAPT Therapeutics was previously known as FLX Bio, Inc. before its name change in May 2019.

Human Longevity (HLI) is a health intelligence company focused on advancing proactive healthcare through genomic insights. Founded in 2013 and based in San Diego, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with machine learning, to enhance medical practices and foster discoveries in health. The company’s primary offerings include the HLI Health Nucleus, a clinical research center that integrates whole-genome sequencing, advanced imaging, and personalized health data to provide a detailed view of individual health. HLI also addresses significant health issues, such as cancer, diabetes, obesity, heart and liver diseases, and dementia, by leveraging DNA sequencing and expert analysis. Through its innovative approach, HLI aims to improve health outcomes and transition healthcare from reactive to proactive strategies.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, that specializes in the discovery, development, and commercialization of biotherapeutics, primarily for cancer treatment. The company’s leading candidates include ZW25, a bispecific antibody currently undergoing Phase I and II clinical trials targeting various cancers, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs advanced computational biotechnology techniques, utilizing proprietary molecular modeling and high-performance computing to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships and collaborations with several major pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Founded in 2003, Zymeworks continues to focus on developing innovative solutions for cancer and other serious diseases.

Aitia is a big data analytics company that specializes in providing solutions for the healthcare industry. The firm utilizes advanced analytics to uncover effective treatments and identify the right patient populations. Aitia's Reverse Engineering and Forward Simulation Technology enables the automated extraction of causal network models from observational data, facilitating high-throughput simulations to generate new insights. The company offers real-world outcomes solutions derived from various data sources, including electronic health records and claims data, and supports product development for biopharmaceutical firms, diagnostic companies, and medical device manufacturers. Aitia serves a diverse clientele, including pharmaceutical and biotechnology companies, health plans, hospitals, and accountable care organizations. Founded in 2000 and based in Cambridge, Massachusetts, Aitia operates as a subsidiary of Via Science, Inc.

Cyteir Therapeutics, Inc. focuses on developing innovative therapeutics that harness the biology of DNA repair to treat cancer and address autoimmune diseases through synthetic lethality. The company manufactures targeted therapeutics designed to induce the self-destruction of diseased cells by overwhelming them with DNA damage. Utilizing an integrated drug development platform, Cyteir aims to balance DNA damage and repair mechanisms to achieve therapeutic effects. Its diverse pipeline includes small molecule therapeutics intended for various applications, particularly in hematological malignancies, solid tumors, and chronic autoimmune disorders. Founded in 2012 and headquartered in Lexington, Massachusetts, Cyteir Therapeutics is committed to overcoming significant challenges in oncology, such as minimizing side effects, reducing therapy resistance, and promoting the self-destruction of cancerous cells.

Receptos is a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for developing best- and first-in-class drugs.

Lycera Corp. is a biopharmaceutical company focused on developing small molecule immunomodulatory medicines aimed at treating autoimmune diseases and cancer. Founded in 2006 and based in Ann Arbor, Michigan, with additional offices in New York and Pennsylvania, Lycera is in the preclinical stage and specializes in first-in-class therapies. Its lead drug candidate, LYC-55716, utilizes multiple anti-tumor mechanisms to modulate gene expression, enhancing immune cell function while reducing immunosuppressive effects. The company also develops ATPase modulators for conditions such as rheumatoid arthritis, lupus erythematosus, psoriasis, and inflammatory bowel disease. Lycera's innovative approach seeks to provide oral efficacy without the adverse effects associated with traditional antiproliferative and immunosuppressive treatments.

Arcus Biosciences is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies through insights in immunology. Founded in 2015 by experienced researchers from the biotechnology sector, the company is advancing a pipeline that includes several promising candidates. Notably, it is developing AB928, a dual A2a/A2b adenosine receptor antagonist, and Zimberelimab, an anti-PD-1 monoclonal antibody, both currently in clinical trials. Additionally, Arcus is working on AB154, an anti-TIGIT monoclonal antibody, and AB680, a small-molecule CD73 inhibitor, targeting various cancer types such as non-small cell lung cancer and pancreatic cancer. The company has established partnerships with organizations like Strata Oncology and AstraZeneca to enhance its research efforts and expand its clinical trials. By focusing on the ATP-adenosine pathway, which plays a crucial role in tumor immunosuppression, Arcus aims to create and optimize differentiated immuno-oncology therapies for patients.

Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.

CRISPR Therapeutics AG is a gene editing company dedicated to developing transformative gene-based medicines for serious human diseases using its proprietary CRISPR/Cas9 technology. This revolutionary platform allows for precise modifications to genomic DNA, enabling the company to target a variety of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The lead product candidate, CTX001, is an ex vivo CRISPR gene-edited therapy aimed at treating transfusion-dependent beta thalassemia and severe sickle cell disease by engineering patients' hematopoietic stem cells to produce elevated levels of fetal hemoglobin. Additionally, CRISPR Therapeutics is advancing other therapies, including CTX110, an allogeneic CAR-T therapy for certain malignancies, and additional programs targeting conditions such as multiple myeloma, solid tumors, diabetes, and various genetic disorders. The company collaborates with strategic partners such as Bayer Healthcare, Vertex Pharmaceuticals, and ViaCyte, and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG is a gene editing company dedicated to developing transformative gene-based medicines for serious human diseases using its proprietary CRISPR/Cas9 technology. This revolutionary platform allows for precise modifications to genomic DNA, enabling the company to target a variety of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The lead product candidate, CTX001, is an ex vivo CRISPR gene-edited therapy aimed at treating transfusion-dependent beta thalassemia and severe sickle cell disease by engineering patients' hematopoietic stem cells to produce elevated levels of fetal hemoglobin. Additionally, CRISPR Therapeutics is advancing other therapies, including CTX110, an allogeneic CAR-T therapy for certain malignancies, and additional programs targeting conditions such as multiple myeloma, solid tumors, diabetes, and various genetic disorders. The company collaborates with strategic partners such as Bayer Healthcare, Vertex Pharmaceuticals, and ViaCyte, and is headquartered in Zug, Switzerland.

Quanticel Pharmaceuticals is a privately held drug discovery company committed to the development of breakthrough medicines for the treatment of cancer. Quanticel's proprietary platform for single-cell genomic analysis of human cancer is designed to enable the discovery of first-in-class oncology therapeutics.

Flexus is a privately-held biopharmaceutical company focused on the creation, development, and commercialization of novel anti-cancer therapeutics through an innovative application of unexploited insights in immunology. Founded in 2013, Flexus is headquartered in San Carlos, California.

Sequenta is a biotech company focused on the discovery and development of clinical diagnostics that leverage a novel platform for understanding immune system status. The advancements in DNA sequencing technology have enabled Sequenta to create innovative methods for measuring the immune cell receptor genes, which exhibit significant variability and play a crucial role in numerous health conditions. This capability positions the company to inform a wide range of clinical decisions through a single, powerful assay. Founded in 2008 by entrepreneurs with previous experience in the biotech sector, Sequenta aims to enhance the understanding of the immune system and improve diagnostic approaches in healthcare.

VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops and commercializes Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory, and inflammatory diseases. It provides Motolimod, a lead investigational drug to mobilize a patient's own immune system by directly activating myeloid dendritic cells, monocytes, and natural killer cells to fight cancer. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is based in Seattle, Washington. As of February 28, 2017, VentiRx Pharmaceuticals, Inc. operates as a subsidiary of Celgene Corporation.

Human Longevity (HLI) is a health intelligence company focused on advancing proactive healthcare through genomic insights. Founded in 2013 and based in San Diego, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with machine learning, to enhance medical practices and foster discoveries in health. The company’s primary offerings include the HLI Health Nucleus, a clinical research center that integrates whole-genome sequencing, advanced imaging, and personalized health data to provide a detailed view of individual health. HLI also addresses significant health issues, such as cancer, diabetes, obesity, heart and liver diseases, and dementia, by leveraging DNA sequencing and expert analysis. Through its innovative approach, HLI aims to improve health outcomes and transition healthcare from reactive to proactive strategies.

Epizyme, Inc. is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing epigenetic medicines for cancer and other diseases. The company has achieved a significant milestone with its approved product, Tazemetostat, which is used for treating metastatic or locally advanced epithelioid sarcoma in the United States. Additionally, Tazemetostat is being investigated in combination therapies for various cancers, including relapsed and refractory follicular lymphoma and high-risk diffuse large B-cell lymphoma. Epizyme is also engaged in developing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, alongside inhibitors targeting PRMT5 and PRMT1 for solid tumors and blood cancers. The company collaborates with several industry leaders and research organizations to advance its innovative therapeutic programs, reflecting its commitment to translating epigenetic research into effective treatments. Founded in 2007, Epizyme aims to reshape cancer treatment through its focus on molecularly targeted drugs.

NantHealth is a healthcare company focused on providing an evidence-based platform for diagnostics and precision medicine. By integrating science and technology, NantHealth empowers physicians, patients, payers, and researchers to overcome traditional barriers in healthcare. The company develops software and hardware solutions that collect, index, analyze, and interpret various data points—molecular, financial, clinical, and operational—to enhance decision-making. Additionally, NantHealth offers specialized solutions for cancer care and payer management, aiming to deliver personalized and genomically-informed healthcare. Their approach is designed to improve diagnostic accuracy and transform clinical delivery, ultimately promoting wellness and advancing next-generation healthcare solutions.

Atara Biotherapeutics is an off-the-shelf T-cell immunotherapy company based in South San Francisco, California, focused on developing innovative treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead product, tabelecleucel (tab-cel), is currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, with additional development for other EBV-related hematologic malignancies and solid tumors, such as nasopharyngeal carcinoma. Atara is also advancing next-generation CAR T immunotherapies, addressing various conditions including mesothelin-targeted therapies for solid tumors and treatments for B-cell lymphomas. Other notable candidates include therapies for multiple sclerosis and several viral infections. The company collaborates with esteemed institutions such as Memorial Sloan Kettering Cancer Center and Bayer AG to enhance its research and development efforts. Founded in 2012, Atara Biotherapeutics is committed to transforming the treatment landscape for serious diseases through its robust clinical and scientific initiatives.

Atara Biotherapeutics is an off-the-shelf T-cell immunotherapy company based in South San Francisco, California, focused on developing innovative treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead product, tabelecleucel (tab-cel), is currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, with additional development for other EBV-related hematologic malignancies and solid tumors, such as nasopharyngeal carcinoma. Atara is also advancing next-generation CAR T immunotherapies, addressing various conditions including mesothelin-targeted therapies for solid tumors and treatments for B-cell lymphomas. Other notable candidates include therapies for multiple sclerosis and several viral infections. The company collaborates with esteemed institutions such as Memorial Sloan Kettering Cancer Center and Bayer AG to enhance its research and development efforts. Founded in 2012, Atara Biotherapeutics is committed to transforming the treatment landscape for serious diseases through its robust clinical and scientific initiatives.

Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

NantHealth is a healthcare company focused on providing an evidence-based platform for diagnostics and precision medicine. By integrating science and technology, NantHealth empowers physicians, patients, payers, and researchers to overcome traditional barriers in healthcare. The company develops software and hardware solutions that collect, index, analyze, and interpret various data points—molecular, financial, clinical, and operational—to enhance decision-making. Additionally, NantHealth offers specialized solutions for cancer care and payer management, aiming to deliver personalized and genomically-informed healthcare. Their approach is designed to improve diagnostic accuracy and transform clinical delivery, ultimately promoting wellness and advancing next-generation healthcare solutions.

Acetylon Pharmaceuticals, Inc. is focused on developing small molecule drugs that target epigenetic mechanisms to improve therapeutic outcomes in cancer and other serious diseases. Established in 2008 and headquartered in Boston, Massachusetts, the company has created a proprietary platform that has led to a portfolio of optimized selective compounds for oral administration, specifically targeting Class I and Class II histone deacetylases. Among its lead drug candidates are ACY-1215 and ACY-241, which are selective HDAC6 inhibitors currently undergoing Phase 2 and Phase 1b clinical trials for the treatment of multiple myeloma. Acetylon Pharmaceuticals operates as a subsidiary of Celgene Corporation, emphasizing its commitment to addressing critical unmet medical needs through innovative epigenetic therapies.

Tengion is a clinical-stage biotechnology company focused on the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Neo-Bladder Augment, which aims to assist children with neurogenic bladder resulting from spina bifida and adults with similar conditions due to spinal cord injuries. An earlier academic study on a urinary Neo-Bladder Augment was published in The Lancet in April 2006, highlighting its potential benefits. Tengion also holds an effective investigational new drug application for its Neo-Urinary Conduit and anticipates initiating a Phase 1 clinical trial for bladder cancer patients requiring bladder removal.

Acetylon Pharmaceuticals, Inc. is focused on developing small molecule drugs that target epigenetic mechanisms to improve therapeutic outcomes in cancer and other serious diseases. Established in 2008 and headquartered in Boston, Massachusetts, the company has created a proprietary platform that has led to a portfolio of optimized selective compounds for oral administration, specifically targeting Class I and Class II histone deacetylases. Among its lead drug candidates are ACY-1215 and ACY-241, which are selective HDAC6 inhibitors currently undergoing Phase 2 and Phase 1b clinical trials for the treatment of multiple myeloma. Acetylon Pharmaceuticals operates as a subsidiary of Celgene Corporation, emphasizing its commitment to addressing critical unmet medical needs through innovative epigenetic therapies.

Avila Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in the design and development of covalent drugs targeting viral infections, cancers, and autoimmune diseases. One of its key products is AVL-181, a small molecule designed to inhibit the protease of the hepatitis C virus. Founded in 2006, Avila Therapeutics has entered into a strategic alliance with Sanofi-Aventis and, as of 2012, operates as a subsidiary of Celgene Corporation. The company's innovative approach focuses on creating therapies that can provide significant benefits in the treatment of challenging medical conditions.

Acceleron Pharma Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company is known for luspatercept-aamt, marketed as REBLOZYL, which treats anemia in adult patients with beta-thalassemia. Additionally, it is developing luspatercept-aamt for myelodysplastic syndromes and myelofibrosis, while Sotatercept targets pulmonary arterial hypertension. Acceleron is also advancing ACE-083, a neuromuscular candidate in Phase II trials aimed at Charcot-Marie-Tooth disease. The company's research focuses on biotherapeutics that influence the growth of bone, muscle, fat, and blood vessels to address conditions such as cancer-related bone and muscle loss, as well as various metabolic disorders. Founded in 2003 and based in Cambridge, Massachusetts, Acceleron has established collaborations with Celgene Corporation and Fulcrum Therapeutics to enhance its therapeutic offerings in the pulmonary disease space.

Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of therapies targeting cellular metabolism, particularly in cancer and rare genetic disorders. The company offers TIBSOVO, an oral targeted inhibitor approved for treating relapsed or refractory acute myeloid leukemia (AML) and newly diagnosed AML, as well as IDHIFA, which targets AML patients with specific genetic mutations. Agios is advancing multiple clinical programs, including TIBSOVO for frontline AML and cholangiocarcinoma, and developing mitapivat for pyruvate kinase deficiency and thalassemia. Other investigational compounds include vorasidenib for solid tumors and AG-270 for specific cancer types. Agios employs a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for successful early clinical proof of concept and accelerated approvals. The company was originally established in 2007 under the name Cancer Metabolism Therapeutics before rebranding to Agios Pharmaceuticals in 2008.

Abraxis BioScience, Inc. is a biotechnology company focused on the discovery, development, and delivery of innovative therapeutics and core technologies aimed at treating cancer and other critical illnesses. The company is best known for its flagship product, Abraxane, a nanoparticle chemotherapeutic compound utilizing a proprietary tumor-targeting technology platform, specifically designed for the treatment of metastatic breast cancer. In addition to Abraxane, Abraxis BioScience has several clinical product candidates in development, including ABI-008, a solvent-free form of docetaxel for hormone-refractory prostate cancer and metastatic breast cancer; ABI-009, an mTOR inhibitor for solid tumors; ABI-010, which targets heat shock protein 90 to combat multiple cancers; ABI-011, a thiocolchicine dimer for disrupting microtubule dynamics; and Coroxane, aimed at treating coronary and peripheral artery restenosis. The company has established strategic partnerships with several pharmaceutical firms to enhance its research and development efforts. Abraxis BioScience, which was formerly known as New Abraxis, Inc., is headquartered in Los Angeles, California, and was acquired by Celgene in 2010.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of therapies targeting cellular metabolism, particularly in cancer and rare genetic disorders. The company offers TIBSOVO, an oral targeted inhibitor approved for treating relapsed or refractory acute myeloid leukemia (AML) and newly diagnosed AML, as well as IDHIFA, which targets AML patients with specific genetic mutations. Agios is advancing multiple clinical programs, including TIBSOVO for frontline AML and cholangiocarcinoma, and developing mitapivat for pyruvate kinase deficiency and thalassemia. Other investigational compounds include vorasidenib for solid tumors and AG-270 for specific cancer types. Agios employs a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for successful early clinical proof of concept and accelerated approvals. The company was originally established in 2007 under the name Cancer Metabolism Therapeutics before rebranding to Agios Pharmaceuticals in 2008.

Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing oncology therapeutics, particularly for hematological malignancies. It is known for its lead compound, romidepsin, a late-stage drug candidate that belongs to a new class of anti-cancer agents called histone deacetylase (HDAC) inhibitors. Romidepsin has demonstrated potential efficacy in treating various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. The company retains exclusive worldwide rights to romidepsin, which is a potent inhibitor of multiple classes of HDACs. Gloucester Pharmaceuticals aims to advance its drug candidates through regulatory approval and commercialization to address critical needs in cancer treatment.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Pharmion is a global biotech company that is dedicated to the hematology and oncology communities. We work in partnership with a network of scientific and clinical advisors to identify and develop products for global hematology and oncology markets. To expand each product's potential, we have established our own regulatory, development and sales and marketing organizations in the United States, Europe, and Australia, and we have developed a third-party distributor network to serve the hematology and oncology markets in 20 additional countries throughout the Middle East, Asia, and Latin America. The global capabilities within our sales, marketing and distribution organization distinguishes us from other companies of a similar size. With our international network we can reach physicians and their patients in more than 30 countries. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on licensing, developing, and commercializing therapeutic products for the treatment of hematology and oncology patients. Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients’ quality of life.

Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.

Anthrogenesis, based in Cedar Knolls, New Jersey, is a biotherapeutics company that has developed proprietary methods for collecting, processing and storing stem cells and other valuable biomaterials derived from human placental tissue. Anthrogenesis is focused on developing and delivering therapies using stem cells sourced from human placental tissue to treat cancers and immunological, metabolic and inflammatory diseases. Anthrogenesis has demonstrated that the human placenta is an abundant source of biotherapies, including early stage stem cells and other biomaterials for organ and tissue repair. Anthrogenesis also operates Lifebank, a state-licensed blood bank that banks stem cell transplant units derived from placental tissue and in some cases, blood from the umbilical cord that is collected immediately after birth.

Signal Pharmaceuticals is a biopharmaceutical company based in California, founded by David Anderson, Alan Lewis, Mark Carmen, and Jackie Johnson. It specializes in the research and development of small-molecule drugs aimed at regulating gene expression associated with various diseases. The company was acquired by Celgene in 2009, which has allowed it to further its mission in the biopharmaceutical field.